EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY-NC 4.0

Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: Study Protocol of the International AnTi‐FREEZE Study

Franka M Goossens iD, Kaylena A Ehgoetz Martens, Bastiaan R Bloem, Rick C Helmich, Erika E Howe iD, Roy P C Kessels iD, Melvyn Roerdink, Annie G Bryant, James M Shine, Anouk Tosserams, Simon J G Lewis, Jorik Nonnekes

European Journal of Neuroscience · 2026

DOI: 10.1111/ejn.70630 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift European Journal of Neuroscience, 2026. Verfasst von Franka M Goossens und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rehabilitation, Center of Expertise for Parkinson and Movement Disorders, Donders Institute for Brain, Cognition and Behaviour, Radboud…. Hauptthemen laut MEDLINE: Adrenergic Uptake Inhibitors, Arousal, Atomoxetine Hydrochloride, Gait Disorders, Neurologic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Michael J. Fox Foundation for Parkinson's Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Freezing of gait (FOG) is a burdensome Parkinson's disease (PD) symptom. Gait control in people with PD relies on compensation from cognitive, sensory and limbic networks. Their integration is influenced by the noradrenergic ascending arousal system, modulated by the locus coeruleus. In PD, locus coeruleus degeneration has been linked to increased FOG severity. Atomoxetine, a selective noradrenaline reuptake inhibitor, may provide a novel therapeutic approach for FOG. However, to date, studies on atomoxetine's effect on FOG have been inconsistent and had small sample sizes. This study will evaluate the effects of atomoxetine on FOG severity, both in the dopaminergic OFF‐ and ON‐states. Moreover, we will investigate its mode of action by examining its influence on functional network topology. Additionally, we will examine clinical and imaging markers associated with an individual's treatment response. Sixty patients with frequent FOG will be recruited for a multicentre, single‐dose, double‐blind, placebo‐controlled, crossover clinical trial. Assessments include clinimetrics, cognition, MDS‐UPDRS III, gait assessments, pupillometry and neuroimaging, conducted in the dopaminergic OFF‐ and ON‐states. The primary outcome is FOG severity in the dopaminergic OFF‐state, quantified based on the percentage of time spent frozen during gait assessments. Resting‐state fMRI is conducted to assess network integration and segregation across brain regions and task‐fMRI to reveal neural circuitry changes during FOG. Lastly, locus coeruleus and substantia nigra integrity will be assessed using structural MRI. This study will provide insights into the role of the noradrenergic ascending arousal system and potentially identify a novel pharmaceutical treatment pipeline for FOG in PD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenergic Uptake InhibitorsArousalAtomoxetine HydrochlorideGait Disorders, NeurologicParkinson DiseaseFemaleHumansMaleCross-Over StudiesDouble-Blind MethodLocus CoeruleusMagnetic Resonance ImagingClinical Trials, Phase III as TopicRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Parkinson's diseaseatomoxetinefreezing of gaitnetwork connectivitynoradrenergic arousal system

Substanzen

Adrenergic Uptake InhibitorsAtomoxetine Hydrochloride

Autor:innen und Institutionen

  • Department of Rehabilitation, Center of Expertise for Parkinson and Movement Disorders, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Donders Centre for Cognitive Neuroimaging, Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, the Netherlands.
  • Department of Kinesiology and Health Sciences, University of Waterloo, Waterloo, Ontario, Canada.
  • Department of Neurology, Center of Expertise for Parkinson and Movement Disorders, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Donders Centre of Cognition, Donders Institute for Brain, Cognition, and Behaviour, Radboud University, Nijmegen, the Netherlands.
  • Vincent van Gogh Institute for Psychiatry, Venray, the Netherlands.

ORCID-Profile: Franka M Goossens, Erika E Howe, Roy P C Kessels

Förderung

  • Michael J. Fox Foundation for Parkinson's Research

Zitieren

APA

Goossens, F. M., Ehgoetz Martens, K. A., Bloem, B. R., Helmich, R. C., Howe, E. E., Kessels, R. P. C., Roerdink, M., Bryant, A. G., Shine, J. M., Tosserams, A., Lewis, S. J. G., & Nonnekes, J. (2026). Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: Study Protocol of the International AnTi‐FREEZE Study. European Journal of Neuroscience. https://doi.org/10.1111/ejn.70630

Vancouver

Goossens FM, Ehgoetz Martens KA, Bloem BR, Helmich RC, Howe EE, Kessels RPC, et al. Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: Study Protocol of the International AnTi‐FREEZE Study. European Journal of Neuroscience. 2026. doi:10.1111/ejn.70630

BibTeX
@article{Goossens2026,
  author = {Goossens, Franka M and Ehgoetz Martens, Kaylena A and Bloem, Bastiaan R and Helmich, Rick C and Howe, Erika E and Kessels, Roy P C and Roerdink, Melvyn and Bryant, Annie G and Shine, James M and Tosserams, Anouk and Lewis, Simon J G and Nonnekes, Jorik},
  title = {Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: Study Protocol of the International AnTi‐FREEZE Study},
  journal = {European Journal of Neuroscience},
  year = {2026},
  doi = {10.1111/ejn.70630}
}
Kostenlos starten →